Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA) for regulatory approval. The submission has qualified for the NMPA's green channel pathway, an expedited review process designed to accelerate approval of innovative medical technologies addressing significant clinical needs.
This milestone marks a key step in Ventripoint's global expansion strategy, targeting China, one of the world's largest healthcare markets. Cardiovascular disease is the leading cause of mortality in China, affecting an estimated 330 million patients. Echocardiography is widely used due to its cost-effectiveness and scalability, but variability in image interpretation and limited access to advanced modalities like MRI create demand for AI-driven tools that improve diagnostic accuracy and workflow efficiency.
VMS+ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by Ventripoint's proprietary Knowledge Based Reconstruction technology, the platform enables clinicians to assess all four heart chambers accurately, supporting diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
"We are excited to take this important step toward bringing VMS+ 4.0 to the Chinese market," said Paul Gibson, Chief Technology Officer of Lishman Global Inc. "Qualification for the NMPA's green channel underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption."
Hugh MacNaught, President and CEO of Ventripoint Diagnostics, added: "Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy. China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly."
The company will provide further updates as the regulatory review process progresses. Ventripoint's VMS+ products are commercially available in the U.S., Europe, and Canada and are compatible with ultrasound systems from any vendor.
